乐普医疗子公司与丹麦Sidera签署授权许可协议

Core Insights - Lepu Medical announced a licensing agreement for its MWN105 injection with Denmark's SideraBioAps, granting exclusive rights for development and commercialization outside Greater China [1] - The initial payment and recent milestone payments total $35 million, with SideraBioAps acquiring a 9.99% equity stake in Shanghai Minwei Biotechnology [1] - SideraBioAps is set to pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1]